Showing results (211-220 of 335) with videos related to
Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trialPatrick J Loehrer, Yang Feng, Higinia Cardenes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2014
A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphomaDonald W Northfelt, Ramesh K Ramanathan, Peter A Cohen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsRamesh K Ramanathan, Merrill J Egorin, Charles Erlichman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancerC P Belani, C M Kearns, E G Zuhowski, et al.Clinical Therapeutics|January 30, 2010
Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction studyKarthik Venkatakrishnan, Michael Rader, Ramesh K Ramanathan, et al.Seminars in Oncology|January 14, 1998
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagusC P Belani, J D Luketich, R J Landreaneau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomaManish A Shah, Ramesh K Ramanathan, David H Ilson, et al.Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.Cancer Chemotherapy and Pharmacology|September 23, 2011
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic functionCindy L O'Bryant, Paul Haluska, Lee Rosen, et al.Clinical Colorectal Cancer|August 24, 2011
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancerRajesh Sehgal, Barry C Lembersky, Kiran K Rajasenan, et al.Pageof 34